<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;VA/DoD clinical practice guideline for management of bipolar disorder in adults.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Management of Bipolar Disorder Working Group. VA/DoD clinical practice guideline for management of bipolar disorder in adults. Washington (DC): Department of Veterans Affairs, Department of Defense; 2010 May. 176 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Behavior therapy  (94.33); Bipolar disorder, unspecified  (296.80); Bipolar I disorder, most recent episode (or current) depressed, unspecified  (296.50); Bipolar I disorder, most recent episode (or current) manic, unspecified  (296.40); Bipolar I disorder, most recent episode (or current) mixed, unspecified  (296.60); Family therapy  (94.42)"/><FieldValue Value="MSH: Anticonvulsants ; Antidepressive Agents ; Antipsychotic Agents ; Behavior Therapy ; Bipolar Disorder ; Cognitive Therapy ; Diagnosis, Dual (Psychiatry) ; Diagnostic and Statistical Manual of Mental Disorders ; Electroconvulsive Therapy ; Family Therapy ; Hospitalization ; Lithium ; Medical History Taking ; Medication Therapy Management ; Patient Education as Topic ; Psychiatric Status Rating Scales ; Psychotherapy ; Severity of Illness Index "/><FieldValue Value="MTH: Anticonvulsants ; Antidepressive Agents ; Bipolar Disorder ; Cognitive Therapy ; Dual diagnosis (psychiatry) ; Electroconvulsive Therapy ; Family psychotherapy ; Hospitalization ; Lithium ; Mixed bipolar I disorder ; Patient education (procedure) ; Psychotherapy "/><FieldValue Value="SNOMEDCT_US: Anti-psychotic agent  (10784006); Anti-psychotic agent  (372482001); Anticonvulsant  (255632006); Anticonvulsant  (63094006); Antidepressant  (36236003); Antidepressant  (372720008); Behavioral therapy  (166001); Bipolar disorder  (13746004); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Depressed bipolar I disorder  (49468007); Electroconvulsive therapy  (23835007); Family psychotherapy procedure  (108313002); Family psychotherapy procedure  (51484002); Inpatient care  (394656005); Interpersonal psychotherapy  (443730003); Lithium  (321719003); Lithium  (85899009); Manic bipolar I disorder  (68569003); Mixed bipolar I disorder  (16506000); Patient education  (311401005); Psychotherapy  (75516001); Social therapy  (243224001); Suicide risk assessment  (225337009)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm462229.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;September 15, 2015 &amp;ndash; Clozapine&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia medicine clozapine, to address continuing safety concerns and current knowledge about a serious blood condition called severe neutropenia. Severe neutropenia is a dangerously low number of neutrophils, white blood cells that help fight infections. Severe neutropenia can be life-threatening. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm426624.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;December 11, 2014 &amp;ndash; Ziprasidone (Geodon and Generics)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is warning that the antipsychotic drug ziprasidone (marketed under the brand name, Geodon, and its generics) is associated with a rare but serious skin reaction that can progress to affect other parts of the body. A new warning has been added to the Geodon drug label to describe the serious condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). See the FDA Drug Safety Communication for a Data Summary and additional information. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Bipolar disorder (BD):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bipolar acute manic, hypomanic, or mixed episode &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bipolar acute depressive episode &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Emergency Medicine" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Social Workers" /><FieldValue Value="Substance Use Disorders Treatment Providers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide recommendations for management of bipolar disorder in adults &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide education and guidance to primary care clinicians, researchers, and other health professionals as they treat patients with bipolar disorder &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (18 years of age or older) with a bipolar disorder (BD) diagnosis including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adults who meet the standard (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [DSM IV-TR]) diagnostic criteria of BD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adults with BD whether they present with mania, hypomania, depression, or mixed episodes, or are in stable condition in maintenance phase &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adults with BD and significant comorbidities, such as substance misuse or anxiety disorder &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consideration is given to the needs of: pregnant women, older people, and those with a range of cognitive impairments &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of signs and symptoms of mania, hypomania, depression, psychotic symptoms, and mixed episodes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complete assessment including using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria; medical and psychiatric comorbidities; current and past medications (including antidepressants) and medication compliance; risk for suicide; substance use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of severity of mania using standardized rating scales &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hospitalization if indicated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacotherapy including lithium, antiepileptics, antipsychotics, and antidepressants &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electroconvulsive therapy (ECT) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychoeducation and psychotherapy including cognitive behavioral therapy, interpersonal and social rhythm therapy, and family therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring for response to therapy and management of side effects &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of maintenance/prophylaxis phase &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of bipolar disorder in older adults &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Remission rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relapse rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk of suicide &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Formulation of Questions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Working Group (WG) developed researchable questions (see Appendix C in the original guideline) and associated key terms to facilitate text-based searches of the literature. Following the template suggested by the Evidence-Based Medicine toolbox, Center for Evidence-Based Medicine, [&lt;a href=&quot;http://www.cebm.net&quot; title=&quot;CEBM Web site&quot;&gt;http://www.cebm.net&lt;/a&gt;], the questions specified:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;P&lt;/strong&gt;opulation &amp;ndash; Characteristics of the target patient population &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;I&lt;/strong&gt;ntervention &amp;ndash; Exposure, diagnostic, or prognosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;C&lt;/strong&gt;omparison &amp;ndash; Intervention, exposure, or control used for comparison &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;O&lt;/strong&gt;utcome &amp;ndash; Outcomes of interest. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;These specifications served as the preliminary criteria for selecting studies. Literature searches were conducted on all topics identified in the algorithm or recommendations of the original guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Selection of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The evidence selection was designed to identify the best available evidence to address each key question and ensure maximum coverage of studies at the top of the hierarchy of study types. Published, peer-reviewed randomized controlled trials (RCTs), as well as meta-analyses and systematic reviews that included RCTs, were considered to constitute the strongest level of evidence in support of guideline recommendations. This decision was based on the judgment that RCTs provide the clearest, most scientifically sound basis for judging comparative efficacy. The WG made this decision while recognizing the limitations of RCTs, particularly considerations of generalizability with respect to patient selection and treatment quality. When available, the search sought out critical appraisals already performed by others that described explicit criteria for deciding what evidence was selected and how it was determined to be valid. The sources that have already undergone rigorous critical appraisal include Cochrane Reviews, Best Evidence, Technology Assessment, and Agency for Healthcare Research and Quality (AHRQ) systematic evidence reports.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition to Medline/PubMed, the following databases were searched: Database of Abstracts of Reviews of Effectiveness (DARE) and Cochrane Central Register of Controlled Trials and PsycINFO. For Medline/PubMed searches, limits were set for language (English), and type of research (RCT, systematic reviews and meta-analysis).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As a result of the literature reviews, articles were identified for possible inclusion. The following inclusion criteria were used for selection of studies:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;English language only of studies performed in United States, United Kingdom, Europe, Australia, Japan, New Zealand &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Full published articles only &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Study populations age limited to adults 18 years of age or older; all races, ethnicities, cultural groups &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Key outcomes cited &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Published from 2002&amp;ndash;2009 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Admissible evidence (study design and other criteria):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Original research studies that provide sufficient detail regarding methods and results to enable use and adjustment of the data and results &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials, systematic reviews (including Evidence-based Practice Center [EPC] and Health Technology Assessment [HTA] reviews), and meta-analyses &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Includes relevant outcomes that can be abstracted from data presented in the articles. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate sample sizes for the study question addressed in the paper. RCTs will be included only if they are initiated with 10 or more subjects. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Quality of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one properly done randomized controlled trial (RCT)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-1&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-designed controlled trial without randomization&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-2&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-designed cohort or case-control analytic study, preferably from more than one source&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Multiple time series evidence with/without intervention, dramatic results of uncontrolled experiment&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Opinion of respected authorities, descriptive studies, case reports, and expert committees&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Overall Quality&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Overall Quality&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-grade evidence (I or II-1) directly linked to health outcome&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Fair&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-grade evidence (I or II-1) linked to intermediate outcome; &lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Moderate-grade evidence (II-2 or II-3) directly linked to health outcome&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Poor&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level III evidence or no linkage of evidence to health outcome&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Net Effect of the Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Net Effect of the Intervention&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Substantial&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;More than a small relative impact on a frequent condition with a substantial burden of suffering;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            A large impact on an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A small relative impact on a frequent condition with a substantial burden of suffering;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            A moderate impact on an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Small&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A negligible relative impact on a frequent condition with a substantial burden of suffering;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            A small impact on an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Zero or Negative&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Negative impact on patients;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            No relative impact on either a frequent condition with a substantial burden of suffering, or an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Preparation of Evidence Tables (Reports) and Evidence Rating&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The results of the searches were organized and data was abstracted from the studies into evidence reports. The reports, as well as copies of the original studies, were provided to the work group (WG) for further analysis. Each reference was appraised for scientific merit, clinical relevance, and applicability to the populations served by the Federal healthcare system. A group of research analysts read and coded each article that met inclusion criteria.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations and Overall Quality Ratings&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Evidence-based practice involves integrating clinical expertise with the best available clinical evidence derived from systematic research. A group of research analysts read and coded each article that met inclusion criteria. The articles were assessed for methodological rigor and clinical importance. Clinical experts from the Department of Veterans Affairs (VA) and Department of Defense (DoD) WG reviewed the results and evaluated the strength of the evidence, considering quality of the body of evidence (made up of the individual studies) and the significance of the net benefit (potential benefit minus possible harm) for each intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The overall strength of each body of evidence that addresses a particular Key Question was assessed using methods adapted from the U.S. Preventive Services Task Force (USPSTF). The number, quality, and size of the studies, as well as the consistency of results between studies and the directness of the evidence were considered in assigning an overall quality [QE] of the evidence (i.e., good, fair, or poor). Consistent results from a number of higher-level studies [LE] that were conducted across a broad range of populations support a high degree of certainty that the results of the studies are true. In such case the entire body of evidence would be considered &quot;good&quot; quality. The quality of the body of evidence was considered &quot;fair&quot; when the results could be due to true effects or to biases present across some or all of the studies. For a &quot;poor&quot; quality body of evidence, any conclusion is uncertain due to serious methodological shortcomings, sparse data, or inconsistent results. (See the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For interventions that were supported by studies of &quot;fair&quot; or &quot;good&quot; quality, the clinical experts evaluated the benefits and the potential harms as demonstrated by the results of the studies. In the final step, the Strength of Recommendation [SR] was determined based on the Quality of the Evidence [QE], and the clinical significance of the Net Benefit [NE] for each intervention. Thus, the grade (i.e., A, B, C, D or I) assigned to guideline recommendations reflects both, the quality of the evidence and the potential clinical benefit that the intervention may provide to patients (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The development of the 2009 update of the Department of Veterans Affairs/Department of Defense (VA/DoD) Clinical Practice Guideline for Bipolar Disorder (BD) followed the steps described in &quot;Guideline for Guidelines,&quot; an internal working document of the VA/DoD Evidence Based Practice Working Group that requires an ongoing review of guideline works in progress.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Offices of Quality and Performance and Patient Care Services of the VA, and the US Army Medical Command, in coordination with the Air Force and Navy members of the Evidence-Based Workgroup, identified clinical leaders to champion the guideline development process. During a preplanning conference call, the clinical leaders defined the scope of the guideline and identified a group of clinical experts from the VA and DoD to form the Management of BD Working Group (WG). Working Group participants were drawn from the fields of Psychiatry, Family Practice, Internal Medicine, Psychology, Social work, Pharmacology and Nursing, from a wide variety of specialty and primary care settings, diverse geographic regions, and both VA and DoD health care systems. This Working Group of the VA/DoD was charged to update the algorithms and recommendations of the original clinical practice guideline published in 2002.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The WG defined a set of clinical questions within the focus area of the guideline. This ensured that the guideline development work outside the meeting focused on issues that practitioners considered important and produced criteria for the search and a protocol for systematic review of the literature.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Working Group participated in an initial face-to-face meeting and two subsequent meetings to reach consensus about the guideline algorithms and recommendations and to prepare a draft update document. The draft continued to be revised by the WG through numerous conference calls and individual contributions to the document. Following the initial effort, an editorial panel of the WG convened to further edit the draft document. Recommendations for the performance or inclusion of specific treatment interventions or services were derived through a rigorous methodological approach that included the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Determining appropriate criteria, such as effectiveness, efficacy, population benefit, or patient satisfaction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reviewing literature to determine the strength of the evidence in relation to these criteria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Formulating the recommendations and grading the level of evidence supporting the recommendation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;This update of the BD Guideline is the product of many months of diligent effort and consensus building among knowledgeable individuals from the VA, DoD, and academia, as well as guideline facilitators from the private sector. An experienced moderator facilitated the multidisciplinary Working Group. The list of participants is included in Appendix E of the original guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Lack of Evidence &amp;ndash; Consensus of Experts&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Where existing literature was ambiguous or conflicting, or where scientific data was lacking on an issue, recommendations were based on the clinical experience of the Working Group.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Final Grade of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Final Grade of Recommendation&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;4&quot;&gt;The Net Benefit of the Intervention&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Substantial&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Small&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Zero or negative&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Fair&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Poor&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations Rating System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Strength of Recommendations Rating System&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A strong recommendation that the clinicians provide the intervention to eligible patients.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;Good evidence was found that the intervention improves important health outcomes and concludes that benefits substantially outweigh harm&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A recommendation that clinicians provide (the service) to eligible patients.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;At least fair evidence was found that the intervention improves health outcomes and concludes that benefits outweigh harm&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation for or against the routine provision of the intervention is made.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;At least fair evidence was found that the intervention can improve health outcomes, but concludes that the balance of benefits and harms is too close to justify a general recommendation&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation is made against routinely providing the intervention to asymptomatic patients.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;At least fair evidence was found that the intervention is ineffective or that harms outweigh benefits&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention. &lt;br /&gt;&#xD;&#xA;            &lt;em&gt;Evidence that the intervention is effective is lacking, or poor quality, or conflicting, and the balance of benefits and harms cannot be determined.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Experts from the Department of Veterans Affairs (VA) and Department of Defense (DoD) reviewed the final draft and their feedback was integrated into the document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Note from the Department of Veterans Affairs and the Department of Defense (VA/DoD) and the National Guideline Clearinghouse (NGC)&lt;/strong&gt;&lt;/em&gt;: The recommendations for the management of bipolar disorder in adults are presented in the form of 6 modules and 3 algorithms. The modules with accompanying recommendations are provided below. See the &lt;a href=&quot;http://www.healthquality.va.gov/bipolar/bd_305_full.pdf&quot; title=&quot;Department of VA Web site&quot; target=&quot;_blank&quot;&gt;original guideline document&lt;/a&gt; for the algorithms and evidence tables associated with selected recommendations, including level and quality of evidence, strength of recommendation, and supporting evidence citations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of recommendation grading (A, B, C, D, I) is defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Module A: Bipolar Acute Manic, Hypomanic, or Mixed Episode&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-1. Person Meets Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition (DSM-IV) Criteria for Bipolar Manic, Hypomanic, or Mixed Episode&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for definitions of manic, hypomanic and mixed episodes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-2. Complete Assessment; Review Current Medication; Assess Suicide Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with a bipolar mania, hypomania or mixed episode require a thorough evaluation to determine level of risk and appropriate acute treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A complete clinical assessment should be obtained for patients with a manic, hypomanic, or mixed episode to include:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Clinical status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medical comorbidities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychiatric comorbidities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychosocial status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Current medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Past medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication compliance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance use &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;A standardized tool combined with a clinical interview should be used to obtain the necessary information about symptoms, symptom severity, and effects on daily functioning that is required to diagnose bipolar disorder (BD) mania/hypomania based on DSM-IV-TR criteria. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess the severity of mania episode using a standardized rating scale (e.g., Young Mania Rating Scale). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider using the same standardized questionnaire to monitor treatment response at follow-up visits, after each change in treatment, and to periodically assess the patient&amp;rsquo;s response to treatment until full remission is achieved. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;For further information on assessment and screening tools for BD and suicide, see: &lt;a href=&quot;http://www.cqaimh.org/stable.html&quot; title=&quot;CQAIMN Web site&quot;&gt;http://www.cqaimh.org/stable.html&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-3. Is Patient Taking Antidepressants or Mania-Inducing Medication? Reduce/Stop Antidepressant Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Stop manic-inducing medications in patients who are experiencing a manic, hypomanic or mixed manic episode.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antidepressants or other manic inducing substances should be stopped in patients experiencing a manic, hypomanic, or mixed manic episode. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antidepressant medications known to be associated with discontinuation syndromes may be tapered over 3 to 5 days rather than being abruptly stopped. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;The most common discontinuation symptoms include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Dizziness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Headache &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Paresthesia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nausea &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diarrhea &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insomnia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Irritability &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-4. Severe Mania, Dangerousness, or Psychotic Features Present?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with BD mania, hypomania, or mixed episode should be assessed for suicidality, acute or chronic psychosis or other unstable or dangerous conditions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Any patient with suicidal ideation or suicide attempts necessitating psychiatric hospitalization should be considered for referral to mental health specialty care. (See Appendix B: &quot;Assessment of Dangerous to Self or Others,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a diagnosis of BD mania who present with severe symptoms with any of the following unstable conditions, need to be referred for urgent/emergent mental health intervention as these are inappropriate for care in the primary care setting:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Delirium &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Marked psychotic symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Severe mania symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Suicidality or homicidality &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Potential for violence (e.g., ideas about or intent to harm others; history of violent behavior; severe agitation or hostility; active psychosis) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance withdrawal or intoxication &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-5. Refer for Hospitalization&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ensure that appropriate care, protocols, and regulatory/policy mandates are followed during diagnosis and stabilization of the patient with a severe or an unstable bipolar manic episode.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Local, state and federal regulations/mandates, as well as guidelines, should be followed when the patient represents a risk to self or others. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with urgent, unstable conditions, severe mania or mixed episode or elevated dangerousness should be referred to a higher level of care (hospitalization). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalization should be considered in patients whose severe mania or mixed episode seriously impairs their ability to care for themselves.&lt;strong&gt; [I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-6. Initiate/Adjust Treatment with Combination of Anti-Psychotic and Anti-Manic Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with severe mania or mixed episode, with or without psychotic features, should be started on a combination of an antipsychotic and another anti-manic agent.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with severe mania should be treated with a combination of antipsychotics and lithium or valproate. These antipsychotics include olanzapine, quetiapine, aripiprazole, or risperidone &lt;strong&gt;[B]&lt;/strong&gt; and may include ziprasidone. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with severe mixed episode should be treated with a combination of antipsychotics and lithium or valproate. These antipsychotics include aripiprazole, olanzapine, risperidone, or haloperidol &lt;strong&gt;[B]&lt;/strong&gt; and may include quetiapine or ziprasidone. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clozapine, with its more serious side effect profile, may be added to existing medications for severe mania or mixed episode if it has been successful in the past or if other antipsychotics have failed. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who are not hospitalized should be reassessed every 2 to 5 days until symptoms improve. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-7. Is Patient Receiving Clinical Effective Medications for Bipolar Mania/Mixed?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For recommended medications see Annotation A-9.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-8. Modify Dose of Medication As Needed&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Adjust anti-manic agents to minimize adverse effects while maximizing clinical effectiveness and maintaining therapeutic plasma concentrations when those are known.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If patient is having intolerable side effects switch to another effective treatment. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess compliance and blood serum concentration to assess if medications are in therapeutic range: &lt;strong&gt;[I]&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The serum trough concentration of lithium should be maintained between 0.8-1.2 mEq/L &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The serum trough concentration of valproate should be maintained between 50-125 mcg/ml &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The serum trough concentration of carbamazepine should be maintained between 4&amp;ndash;12 mcg/ml &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medications without known therapeutic plasma concentrations should be increased until significant improvement is seen, side effects become intolerable or the dose reaches the manufacturer&amp;rsquo;s suggested upper limits. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-9. Initiate/Adjust Treatment with an Anti-Manic Medication&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with mania/hypomania or mixed episode should be started on a medication proven to effectively treat manic and mixed manic symptoms.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;General Considerations&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pharmacotherapy for bipolar mania or mixed episode should start with initiation or optimization of a medication that has been shown to be the most effective in treating bipolar manic episodes while minimizing the potential risks. &lt;strong&gt;[I]&lt;/strong&gt; (see Table A - 2 in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider using the agent(s) that have been effective in treating prior episodes of mania or mixed episode. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ensure that the patient has stopped taking any antidepressant or mania inducing substances. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In selecting a drug treatment regimen for patients with BD, clinicians should be aware of the patient's other psychiatric and medical conditions and should try to avoid exacerbating them. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In selecting a drug treatment regimen for patients with diabetes or obesity consider the risk and benefit of utilizing medications that are less associated with weight gain. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Mania&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with mania should be started on one of the following: lithium, valproate, carbamazepine, aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Mixed Episode&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with mixed episode should be started on one of the following: valproate, carbamazepine, olanzapine, aripiprazole, risperidone, or ziprasidone. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Mania or Mixed Episode&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clozapine, haloperidol and oxcarbazepine may be considered in patients with mania or mixed episode. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lithium or quetiapine may be considered in patients with mixed episode. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medications NOT recommended in patients with mania or mixed episode include topiramate, lamotrigine, and gabapentin. &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-10. Reassess Every One to Two Weeks for at Least 6 Weeks&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ongoing assessment of patients starting treatment for acute bipolar mania, hypomania or mixed episodes should include a reassessment for: &lt;strong&gt;[I]&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The development of depressive symptoms, suicidal ideation or homicidal ideation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Emergence or change in psychotic symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance use &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adverse effects of medications (See Table E - 1 &quot;Adverse Events &amp;ndash; Lithium&quot;; Table E - 4 &quot;Adverse Events Antiepileptic Medications&quot;; and Table E - 6 &quot;Adverse Events - Antipsychotics&quot; in the original guideline document) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication adherence &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medical stability (e.g., blood pressure) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Significant changes in psychosocial circumstances &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reassess patient every 1 to 2 weeks for at least 6 weeks. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ongoing assessment of patients starting treatment for acute bipolar mania or mixed episode may include pertinent laboratory studies (e.g., medication plasma concentrations, urine drug screening, complete blood count [CBC], blood glucose, liver panel, lipid panel) and weight. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-11. Is Patient Responding to Therapy?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Monitor treatment response at 4 to 8 weeks after initiation of treatment, after each change in treatment, and periodically until full remission is achieved. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients who reach full remission, assessment of symptoms should be continued periodically to monitor for relapse or recurrence. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with suicidal ideation should have a careful evaluation of suicide risk. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Providers should give simple educational messages regarding medication therapy (e.g., take daily, understand gradual nature of benefits, continue even when feeling better, do not stop without checking with the provider, and specific instructions on how to address issues or concerns) in order to increase adherence to treatment. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient, family and/or caregiver should be educated about the risk of relapse to mania or hypomania that may occur. They should be instructed on identifying symptoms and the importance of contacting their provider immediately if they notice these symptoms. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-12. Is Patient in Full Remission?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with mania who have been without any significant symptoms of mania for two months should be considered to be in full remission. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with mixed episode who have been without any significant symptoms of mania or depression for two months should be considered to be in full remission. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-13. Assess Adherence, Need for Psychosocial and/or Family Interventions, Adverse Effects, and Psychosocial Barriers to Therapy; Assess Risk for Suicide&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assess adherence to therapy, and other possible causes for partial response or non-response.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients should be followed by a scheduled visit to the clinic periodically, depending on their response to therapy, for a thorough assessment that includes:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Adherence to therapy. Reasons for noncompliance should be explored with the patient. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment of potential adverse effects. &lt;strong&gt;[A]&lt;/strong&gt; (see Table E - 1 &quot;Adverse Events &amp;ndash; Lithium&quot;; Table E - 4 &quot;Adverse Events Antiepileptic Medications&quot;; and Table E - 6 &quot;Adverse Events - Antipsychotics,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring of serum concentration for lithium, valproate, or carbamazepine, and other appropriate blood work to maintain efficacy and avoid toxicity &lt;strong&gt;[A/B]&lt;/strong&gt; (See Annotation A-8) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;For patients receiving antipsychotic medications, monitor weight, body mass index (BMI), waist circumference, blood pressure, plasma glucose and fasting lipids &lt;strong&gt;[A]&lt;/strong&gt;. (See Table E-8 &quot;Monitoring Parameters for Metabolic Adverse Effects in Second Generation Antipsychotics,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment of any changes in patient's family and community support (housing, care givers, employment, income, social networks). &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess for improvement or change of the core symptoms of mania and mixed episode through a clinical interview or the use of a standardized rating scale (e.g., Young Mania Rating Scale). &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with suicidal ideation should have a careful evaluation of suicide risk. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A-14. Add/Change Anti Manic Medication until Stable or Consider Alternative Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients whose mania or mixed episode does not respond to adequate doses of a single medication should be receiving more aggressive medication treatment or hospitalization.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients whose mania does not respond to monotherapy should be considered for consultation/referral with specialty care. (For patient with severe mania or mixed episode &amp;ndash; see Annotation A-6.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reassess for co-occurring medical conditions that may also contribute to greater bipolar illness severity and reduced recovery. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Escalating pharmacotherapy may be considered for patients whose mania/mixed episode or hypomania does not respond to monotherapy. The possible options for escalating pharmacotherapy include:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Switching to another monotherapy may be considered if the patient did not respond to the first medication. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;In patients with mania/hypomania who do not respond to monotherapy, consider combining a non-antipsychotic mood stabilizer (lithium or valproate) with a second generation antipsychotic such as aripiprazole, olanzapine, quetiapine, or risperidone &lt;strong&gt;[A]&lt;/strong&gt; or ziprasidone. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;In patients with mixed episode who do not respond to monotherapy, consider a combination of non-antipsychotics mood stabilizer (lithium or valproate) and a second generation antipsychotic such as aripiprazole, olanzapine, or risperidone &lt;strong&gt;[B]&lt;/strong&gt; or quetiapine or ziprasidone. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clozapine, with its more serious side effect profile, may be combined with valproate or lithium as a treatment of severe mania or mixed episode, if it has been successful in the past or if other antipsychotics have failed. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adjust medications if there is no response within 2 to 4 weeks on an adequate dose of medication. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electroconvulsive therapy (ECT) may be considered for patients with severe mania or patients whose mania is treatment resistant, those patients who express a preference for ECT, and patients with severe mania during pregnancy. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risks and benefits of long-term pharmacotherapy should be discussed prior to starting medication and should be a continued discussion item during treatment. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Module B: Bipolar Acute Depressive Episode&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-1. Person Meets DSM-IV-TR Criteria for Bipolar Depressive Episode&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for definition of a major depressive episode DSM-IV-TR.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-2. Complete Assessment; Review Current Medications; Assess Suicide Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with a bipolar depressive episode require a thorough evaluation to determine level of risk and appropriate treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A complete clinical assessment should be obtained for patients with BD depression episode to include:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Clinical status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medical comorbidities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychiatric comorbidities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychosocial status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Current medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Past medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication compliance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance use &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;See Appendix B: &quot;Assessment of Dangerous to Self or Others,&quot; in the original guideline document. &lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;A standardized tool combined with a clinical interview should be used to obtain the necessary information about symptoms, symptom severity, and effects on daily functioning that is required to diagnose BD depression based on DSM-IV-TR criteria. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider using the same standardized questionnaire to monitor treatment response at 4 to 6 weeks, after each change in treatment, and to periodically assess the patient's response to treatment until full remission is achieved. (For further information on assessment and screening tools for BD and suicide, see: &lt;a href=&quot;http://www.cqaimh.org/stable.html&quot; title=&quot;CQAIMH Web site&quot;&gt;http://www.cqaimh.org/stable.html&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-3. Is The Patient at High Risk of Harming Self or Others?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Identify patients who are at high risk of harm to self or others.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with a possible diagnosis of BD depression should be assessed for suicidality, acute or chronic psychosis or other unstable or dangerous conditions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A referral to emergency services and/or a mental health professional is indicated for patients presenting with any of the following unstable conditions:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Delirium &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Marked psychotic symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Severe depressive symptoms/depression (e.g., catatonia, malnourishment, severe disability) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Suicidality or homicidality &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Potential for violence (e.g., ideas about or intent to harm others; history of violent behavior; severe agitation or hostility; active psychosis) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance withdrawal or intoxication &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;Any patient with suicidal or homicidal ideation or attempts necessitating psychiatric hospitalization should be considered for referral to mental health specialty care. (See Appendix B: &quot;Dangerous to Self or Others,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a possible diagnosis of BD depression who exhibit any of the following characteristics related to psychosis need to be referred for urgent/emergent mental health intervention as these are inappropriate for care in the primary care setting:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Serious delusions (e.g., fixed false beliefs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Visual or (typically) auditory hallucinations &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Confusion (incoherence) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Catatonic behavior (e.g., motor immobility or excessive agitation) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Extreme negativism or mutism &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Peculiar voluntary movement &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Inappropriate affect of a bizarre or odd quality &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-4. Refer for Hospitalization&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ensure that appropriate care, protocols, and regulatory/policy mandates are followed during diagnosis and stabilization of the patient with an unstable bipolar depressive episode. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Local, state and federal regulations/mandates as well as guidelines should be followed when the patient represents a risk to self or other. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with urgent, unstable conditions, severe depression or elevated dangerousness should be referred to a higher level of care (hospitalization). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-5. Is Patient Currently Receiving Clinically Effective Medications for Bipolar Depression?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All patients with BD depression should be treated with medications that have been shown to be effective. For recommendation on modifying medication treatment see Annotation B-7.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-6. Pharmacotherapy for Bipolar Depression&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with a bipolar depressive episode should be treated with medications that have demonstrated efficacy in treating that depressive episode while minimizing the risk of inducing a manic, hypomanic or mixed manic episode.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;General Considerations&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pharmacotherapy for bipolar depression should start with initiation or optimization of a medication that has been shown to be the most effective in treating bipolar depressive episodes, while minimizing the potential risks. &lt;strong&gt;[B]&lt;/strong&gt; (see Table B-2 in the original guideline document.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider using the agent(s) that have been effective in treating prior episodes of depression. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk for mood destabilization or switching to mania should be evaluated and the patient should be monitored closely for emergent symptoms after initiation of pharmacotherapy for a depressive episode. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients with BD depression with psychotic features, an antipsychotic medication should be started. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider adding one of the evidence based psychotherapeutic interventions to improve adherence and patient outcome. &lt;strong&gt;[B]&lt;/strong&gt; (See Module D: Psychosocial Interventions) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In selecting a drug treatment regimen for patients with BD, clinicians should be aware of the patient&amp;rsquo;s other psychiatric and medical conditions and should try to avoid exacerbating them. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In selecting a drug treatment regimen for patients with diabetes or obesity consider the risk and benefit of utilizing medications that are less associated with weight gain. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monotherapy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;Quetiapine, &lt;strong&gt;[A]&lt;/strong&gt;, lamotrigine &lt;strong&gt;[B]&lt;/strong&gt;, or lithium &lt;strong&gt;[B]&lt;/strong&gt; monotherapy should be considered as first-line treatment for adult patients with BD depression. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Olanzapine/fluoxetine combination (OFC) should be considered for treatment of BD depression, but its adverse effects (weight gain, risk of diabetes, hypertriglyceridemia) places this combination as a second-line treatment. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Olanzapine alone may be considered for BD depression, but adverse effects require caution. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence to recommend for or against the use of valproate, carbamazepine, topiramate, risperidone, ziprasidone, or clozapine for BD depression. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aripiprazole is NOT recommended for monotherapy in the treatment of acute bipolar depression, unless there is a history of previous good response during depression without switch to mania or a history of treatment refractory depression. &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Combination Strategies&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;13&quot;&gt;&#xD;&#xA;    &lt;li&gt;Combining lithium with lamotrigine can be considered for patients with BD depression who do not respond to monotherapy. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When patients do not respond to treatment options that have shown better efficacy, antidepressant augmentation with selective serotonin reuptake inhibitor (SSRI), serotonin norepinephrine reuptake inhibitor (SNRI), bupropion, and monoamine oxidase inhibitor (MAOI) can be considered for short-term treatment, monitoring closely for triggering of manic symptoms. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clozapine may be considered for augmentation, using caution regarding metabolic or other adverse effects. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence to recommend for or against use of augmentation with aripiprazole, olanzapine, risperidone, haloperidol, oxcarbazepine, topiramate, ziprasidone, valproate, or carbamazepine for the treatment of bipolar depression. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gabapentin and the tricyclic antidepressants (TCAs) are NOT recommended for monotherapy or augmentation in the treatment of acute bipolar depression, unless there is a history of previous good response during depression without switch to mania or a history of treatment refractory depression. &lt;strong&gt;[D]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-7. Modify Dose or Medication if Indicated, Using Medications Effective for Bipolar Depression&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If patient is having intolerable side effects switch to another effective treatment. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the patient has switched into mania or hypomania or entered a mixed manic state, go to Module A (Acute Mania). &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess compliance and blood serum concentration to assess if medications are in therapeutic range &lt;strong&gt;[I]&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The serum trough concentration of lithium should be maintained between 0.8-1.2 mEq/L. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The serum trough concentration of valproate should be maintained between 50-125 mcg/ml. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The serum trough concentration of carbamazepine should be maintained between 4&amp;ndash;12 mcg/ml. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;If medication is not in therapeutic range, adjust medication to maximum range. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medications without known therapeutic plasma concentrations should be increased until significant improvement is seen, side effects become intolerable or the dose reaches the manufacturer's suggested upper limits. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Partial Response&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adjust medications if there is no response within 2 to 4 weeks on an adequate dose of medication. Adjustment may include:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Augmenting with additional agents (See Annotation B-6) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Discontinue the current agent and switch to another effective medication (See Annotation B-6) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If multiple trials of switching medications or augmentation strategies have not been effective consider ECT. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;Any discontinuation of medication used to treat bipolar depression should be tapered and the patient should be monitored for antidepressant discontinuation syndrome and mood destabilization. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risks and benefits of long term pharmacotherapy should be discussed prior to starting medication and should be a continuing discussion item during treatment. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-8. Reassess Every One to Two Weeks for Six Weeks&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ongoing assessment of patients starting treatment for acute bipolar depression should include a reassessment for: &lt;strong&gt;[I]&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Changes in depressive symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Neurovegetative symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Emerging symptoms of mania/hypomania &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychotic symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Development of suicidal or homicidal ideation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance use &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adverse effects of medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication compliance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medical stability (e.g., blood pressure) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Significant changes in psychosocial circumstances &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reassess patient every 1 to 2 weeks for at least 6 weeks. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ongoing assessment of patients starting treatment for acute bipolar depression may include pertinent laboratory studies (e.g., medication plasma concentrations, urine drug screening, complete blood count (CBC), blood glucose, liver panel, lipid panel) and weight. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-9. Provide Psychoeducation, Psychotherapy, and Family Intervention as Indicated&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Providers should give simple educational messages regarding medication therapy (e.g., take daily, understand gradual nature of benefits, continue even when feeling better, do not stop without checking with the provider, and specific instructions on how to address issues or concerns) in order to increase adherence to treatment. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient, family and/or caregiver should be educated about the risk of switching to mania or hypomania that may occur naturally or as a result of medications. They should be instructed on identifying symptoms and the importance of contacting their provider immediately if they notice these symptoms. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider psychoeducation and care management for patients with BD. &lt;strong&gt;[B]&lt;/strong&gt; For best effect consider offering in a structured group setting with ongoing care/disease management. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who are currently in a depressive episode and are at high risk for non-adherence to medication, should be considered for one of the following evidence-based psychotherapeutic interventions&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Cognitive behavioral therapy (CBT)&lt;strong&gt; [A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Family Therapy &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interpersonal and Social Rhythm Therapy (IPSRT)&lt;strong&gt; [B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-10. Is Patient Responding to Treatment?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Once the patient has demonstrated a response to treatment, continue to monitor progress every 4 to 8 weeks and after each change in treatment until full remission is achieved. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients who reach full remission, assessment of symptoms should be continued periodically to monitor for relapse or recurrence. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with suicidal ideation should have a careful evaluation of suicide risk. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-11. Is Patient in Full Remission?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement &lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with bipolar depression who have been without any significant symptoms of depression for two months should be considered to be in full remission.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Following remission of the depressive episode, it is appropriate to consider withdrawing antidepressant treatment after 4 to 6 months. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-12. Assess Adherence, Side Effects, and Psychosocial Barriers to Therapy; Assess Risk for Suicide&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assess adherence to treatment, and other possible causes for partial response or no-response.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients should be followed by a scheduled visit to the clinic periodically, depending on their response, for a thorough assessment that includes:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Adherence to therapy. Reasons for noncompliance should be explored with the patient. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment of potential adverse effects. &lt;strong&gt;[A]&lt;/strong&gt; (See Table E - 1 &quot;Adverse Events &amp;ndash; Lithium&quot;; Table E - 4 &quot;Adverse Events Antiepileptic Medications&quot;; and Table E - 6 &quot;Adverse Events - Antipsychotics,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring of serum concentration for lithium and other appropriate blood work to maintain efficacy and avoid toxicity (See Table E - 5 &quot;Recommended Pharmacotherapy Monitoring,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;For antipsychotics monitor weight, waist circumference, blood pressure, BMI, plasma glucose and fasting lipids &lt;strong&gt;[C]&lt;/strong&gt;. (See Table E - 8 &quot;Monitoring Parameters and Frequency for Metabolic Adverse Effects Secondary to Second Generation Antipsychotics,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess for co-occurring medical conditions that can mimic or exacerbate BD depression. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment of any changes in patient's family and community support (housing, care givers, employment, income, social networks). &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess for improvement or change of the core symptoms of depression through a clinical interview or the use of a standardized rating scale to determine changes in the severity of depression. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with suicidal ideation should have a careful evaluation of suicide risk. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B-13. Consider ECT or Alternative Therapies; Monitor for Risk for Mood Destabilization&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ECT should be utilized for the treatment of severe and refractory bipolar depression in patients who consent and have no absolute medical contraindications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;ECT should be initiated in patients with severe or refractory bipolar depression who consent and have no absolute medical contraindications. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk for mood destabilization or switching to mania should be evaluated and the patient should be monitored closely for emergent symptoms. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Module C: Maintenance/Prophylaxis Phase&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-1. Adult Person with BD in Symptomatic Remission after an Acute Manic/Hypomanic/Mixed or Depressive Episode&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A structured approach to maintenance management of the patient with BD who has recently experienced an acute episode and is now in remission is recommended. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who have had an acute manic episode should be treated for at least 6 months after the initial episode is controlled and encouraged to continue on life-long prophylactic treatment with medication. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risks and benefits of long term pharmacotherapy should be discussed prior to starting medication and should be a continued discussion item during treatment. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who have had more than one manic episode or with one manic and one depressive episode, or three or more depressive episodes, should be encouraged to continue on life-long prophylactic treatment, as the benefits clearly outweigh the risks. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If medications are to be discontinued, they should be slowly and gradually tapered over at least a 2 to 4 week period, unless medically contraindicated, in order to prevent an episode of BD and/or increase the risk of suicide. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-2. Assess Course of Illness, Treatment History, and Current Clinical Status&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with BD who have achieved remission from an acute episode require a thorough evaluation to determine appropriate maintenance treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A complete clinical assessment should be obtained for patients with BD who are entering the maintenance phase following an acute episode, to include:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Clinical status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medical comorbidities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychiatric comorbidities &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychosocial status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Current medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Past medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Medication compliance &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Suicide risk &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Substance use &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-3. Is Patient Receiving Tolerable and Clinically Effective Medications for Maintaining Remission?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients who are clinically stable and tolerating their medication can be maintained on the agent used in acute treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients who continue to experience sub-threshold symptoms or breakthrough mood episodes may require the addition of another maintenance medication. Certain medications have shown stronger evidence for the prevention of mania or depression. (See Annotation C-4)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-4. Institute Maintenance Medications That Have Demonstrated Clinical Efficacy for at Least 6 Months&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Pharmacotherapy should optimally consist of a clinically effective medication for the prevention of manic and depressive episodes and should be prescribed to patients with BD in the maintenance phase.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Consider using the agent(s) that have been effective in the recent acute phase or in past mood episodes. (See Table C-2 in the original guideline document) &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider reducing to a single medication (monotherapy) that has been shown to be most effective in delaying/preventing relapse while minimizing the potential risks by monitoring the patient closely. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider the pharmacokinetics, adverse effects, and drug-drug interactions when selecting the specific agent(s). &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lithium &lt;strong&gt;[A]&lt;/strong&gt; or olanzapine &lt;strong&gt;[B]&lt;/strong&gt; should be considered as first-line maintenance treatment for adults with BD to delay/prevent the recurrence of mania. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risperidone long-acting intramuscular (IM) injection should be considered for patient with frequent relapses. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aripiprazole &lt;strong&gt;[B]&lt;/strong&gt; may be considered as a second line treatment to prevent or delay the recurrence of mania. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lithium, or lamotrigine, should be considered as a first-line treatment to prevent or delay the recurrence of bipolar depression. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Olanzapine may be considered as a second line treatment to prevent/delay bipolar depressive episodes. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quetiapine augmentation of valproate or lithium should be considered a first-line maintenance treatment for adults with BP to maintain remission and prevent new episodes of all types. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adding olanzapine to lithium or valproate may be used in maintenance treatment to delay or prevent symptomatic relapse. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients with a history of severe or recent mania, lamotrigine should be used in combination with lithium, olanzapine, or aripiprazole. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Valproate and carbamazepine may also be considered as alternatives for maintenance medication. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is insufficient evidence to recommend for or against other antipsychotic or anti-epileptic agents in the maintenance treatment of BD. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-5. Assess for Adverse Events within 2 Weeks&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assess for adverse effects and tolerability after any change of treatment strategy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Using a standardized clinical tool in addition to a clinical interview, assess for response to treatment, adherence to treatment and adverse effects of treatment after initiating or changing treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Identified side effects should be managed to minimize or alleviate if possible. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;See Table E - 1 &quot;Adverse Events &amp;ndash; Lithium&quot;; Table E - 4 &quot;Adverse Events Antiepileptic Medications&quot;; and Table E - 6 &quot;Adverse Events - Antipsychotics,&quot; in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-6. Provide Psychoeducation, Psychotherapy, and Family Intervention as Indicated&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Providers should give simple educational messages regarding medication therapy (e.g., take daily, understand gradual nature of benefits, continue even when feeling better, do not stop without checking with the provider, and specific instructions on how to address issues or concerns) in order to increase adherence to treatment. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider psychoeducation and care management for patients with BD. &lt;strong&gt;[B]&lt;/strong&gt; For best effect consider offering in a structured group setting with ongoing care/disease management &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients on prophylactic medications, who are recovering or have recovered from a manic or hypomanic episode, as well as those currently in a depressive episode and who are at high risk for non-adherence to medication; should be considered for one of the following evidence-based psychotherapeutic interventions:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Cognitive behavioral therapy (CBT) &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Family therapy &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interpersonal and Social Rhythm Therapy (IPSRT) &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-7. Assess Response after 1-3 months; Monitor All Medications and Manage Adverse Effects. Monitor and Encourage Adherence. Discuss with Patient Risks and Benefits of Long-Term Pharmacotherapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients' adherence to treatment should be assessed. Barriers to adherence should be addressed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients whose BD is in remission should be followed by a scheduled visit to the clinic every 1 to 3 months with a thorough assessment of current and recent symptoms. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All patients on medication should be monitored for potential adverse effects. &lt;strong&gt;[B]&lt;/strong&gt; (See Module E: Table E - 1 &quot;Adverse Events &amp;ndash; Lithium&quot;; Table E - 4 &quot;Adverse Events Antiepileptic Medications&quot;; and Table E - 6 &quot;Adverse Events - Antipsychotics,&quot; in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor serum concentration for lithium, carbamazepine, or valproate and other appropriate blood work every 3 to 6 months to maintain efficacy and avoid toxicity. &lt;strong&gt;[A/B]&lt;/strong&gt; (see Table E - 5 &quot;Recommended Pharmacotherapy Monitoring,&quot; in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For antipsychotics monitor weight (BMI), waist circumference, blood pressure, plasma glucose and fasting lipids annually &lt;strong&gt;[C]&lt;/strong&gt;. (See Table E - 8 &quot;Monitoring Parameters and Frequency for Metabolic Adverse Effects Secondary to Second Generation Antipsychotics,&quot; in the original guideline document) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adherence to medication therapy should be routinely evaluated at each visit. Reasons for noncompliance should be explored with the patient. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess any changes in patient's family and community support (e.g., housing, care givers, employment, income, social networks). &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-8. Is There Any Medical or Psychiatric Comorbidity?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Identify any medical or psychiatric comorbidity in patients receiving maintenance treatment for BD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Manage co-occurring substance use disorders, including nicotine disorders in patients with BD using the VA/DoD guidelines for substance use disorders and for tobacco use while continuing to manage the BD according to this guideline. Addiction focused treatment should be coordinated with the treatment of BD. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refer patients with other co-occurring major psychiatric illnesses to specialty care. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refer patients who have had significant suicidality or homicidality to specialty care. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Because of possibility of adverse drug-drug interactions, the provider should consider all current medications including over-the-counter (OTC) medication and nutritional supplements whenever new medications are prescribed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In selecting a drug treatment regimen for patients with BD, clinicians should be aware of the patient&amp;rsquo;s other psychiatric and medical conditions and should try to avoid exacerbating them. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In selecting a drug treatment regimen for patients with diabetes or obesity consider the risk and benefit of utilizing medications that are less associated with weight gain. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary care providers should continue to follow patients who are referred to specialty care, and should coordinate the management of all of their health conditions. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-9. Is Patient in Recurrence and Meets DSM-IV-TR Criteria for Bipolar Episode?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients who experience a recurrence, manage their care according to the respective module.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Module A - for management of Bipolar Acute Manic/Hypomania/Mixed episode.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Module B - for management of Bipolar Acute Depressive Episode.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-10. Optimize Medication Regimen and Psychotherapy Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;If patient is having intolerable side effects switch to another effective treatment. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If symptoms of mania, hypomania, or depression re-occur but do not meet criteria for a relapse adjust current treatment as follows:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Assess compliance and if medications are in therapeutic range &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess for other factors that may cause the symptoms (i.e., medical condition or substance use) &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If medication is not in therapeutic range adjust medication to maximum range &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider adding one of the evidence based psychotherapeutic interventions &lt;strong&gt;[B]&lt;/strong&gt; (See Module D - Psychosocial Interventions) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider adding an augmenting agent (quetiapine or olanzapine) &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider switching to another treatment that is effective for maintenance treatment. &lt;strong&gt;[I]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risks and benefits of long-term pharmacotherapy should be discussed prior to starting medication and during treatment. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C-11. Consider Discontinuing Medications That Are Not Critical for Mood Stabilization while Maintaining Symptomatic and Functional Remission. Continue Follow-Up to Prevent Recurrence and Promote Recovery and Rehabilitation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medications that are believed not to be critical for mood stabilization are recommended to be gradually tapered one at a time. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In all of these cases the taper should be done gradually with close observation by the provider, patient, and if possible, other objective sources of information (e.g., spouses). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If symptoms re-occur, alternative medications with lower side effects burden or using somewhat lower doses should be considered. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Module D: Psychosocial Interventions&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Psychoeducation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient should receive psychoeducation that emphasizes: &lt;strong&gt;[B]&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The importance of active involvement in their treatment &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The nature and course of their bipolar illness &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The potential benefit and adverse effects of treatment options &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The recognition of early signs of relapse &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Behavioral interventions that can lessen the likelihood of relapse including careful attention to sleep regulation and avoidance of substance misuse &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;With the patient's permission, family members or significant other should be involved in the psychoeducation process. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A structured group format in providing psychoeducation and care management for patients with clinically significant mood symptoms should be considered. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Psychotherapy Strategies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Cognitive Behavioral (CBT)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cognitive behavioral treatment may be considered as an adjunct to pharmacotherapy for patients with BD who have achieved remission from an acute manic episode and who have had fewer than 12 previous BD acute episodes &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation of CBT should include components of:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Education regarding symptoms, course and treatment of BD &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Scheduling of pleasurable events to alleviate inactivity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Teaching the skill of cognitive re-structuring &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Learning to identify maladaptive thoughts and challenge them on logical grounds &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Learning to replace maladaptive thoughts with balanced or adaptive thinking &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Problem solving &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Learning to detect the earliest signs of recurrence and implement early intervention plans. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;In considering patients for CBT it is recommended that careful screening for hypomanic episodes be conducted (dynamism, persuasiveness, productiveness) as there is some evidence to support that CBT is less effective with these patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CBT can be considered as an approach to reduce and prevent depressive symptoms in BD rather than manic symptoms as it has been found to be most effective in depression. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Interpersonal and Social Rhythm Therapy (IPSRT)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Interpersonal and social rhythm therapy (IPSRT) may be considered for patients with BD who have achieved remission from an acute manic episode and are maintained on prophylactic medication. &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;IPSRT should contain the following components:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patients should complete the Social Rhythm Metric questionnaire which is a self-report instrument for tracking and quantifying daily and nightly routines, along with ratings of mood. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Providers need to assist patients in keeping regular routines (e.g., bed times, wake times, exercise) and minimizing the impact of events that could disrupt their moods and daily/nightly stability. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Providers need to maintain an interpersonal focus that concerns the resolution of the patient&amp;rsquo;s current problems (e.g., how to communicate better with one&amp;rsquo;s spouse) and developing strategies for preventing the same problems from recurring in the future. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Family Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Couples and families who are coping with BD should be considered for family therapy either on an inpatient or outpatient basis. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Family focused therapy should contain the following four components:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Initial assessment &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychoeducation about the nature, course, and treatment of BD, including the importance of medication consistency, identifying early warning signs of relapse, and implementing relapse prevention strategies &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Communication and enhancement skills, notably role playing and rehearsal of tools for active listening and expressing positive or negative feelings &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Problem solving skills &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Chronic Care Models Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients, who have BD, should be offered chronic care model-based interventions &lt;strong&gt;[B]&lt;/strong&gt;, especially when patients are more symptomatic, or were recently hospitalized. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Module E: Pharmacotherapy Interventions&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for detailed information about medications used to treat BD, including lithium, antiepileptics, antipsychotics, and antidepressants.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Electroconvulsive Therapy (ECT)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;ECT may be considered for manic patients who are severely ill and/or whose mania is treatment resistant, those patients who express a preference for ECT and patients with severe mania during pregnancy. &lt;strong&gt;[C]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ECT should be used only to achieve rapid and short-term improvement of severe symptoms after an adequate trial of other treatment options has proven ineffective and/or when the condition is considered to be potentially life-threatening. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ECT for BD is indicated as the primary therapy in the following &lt;strong&gt;[A]:&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Psychotic symptoms &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Catatonia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Severe suicidality &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Food refusal leading to nutritional compromise &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;History of prior positive response to ECT &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;ECT is considered as first line therapy for the following conditions &lt;strong&gt;[B]&lt;/strong&gt;:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Need for rapid, definitive treatment response on either medical or psychiatric grounds &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Risks of other treatments outweigh the risks of ECT &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adequate trial of other treatment options (including drugs) has proven ineffective &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patient preference &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;ECT may be considered as augmented therapy in the following &lt;strong&gt;[B]&lt;/strong&gt;:&#xD;&#xA;    &lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Treatment failure &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Unavoidable adverse effects using alternative treatments &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Deterioration of patient's condition such that the first criterion is met &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Module F: Bipolar Disorder in Older Adults&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Action Statement&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Older adults with BD who are receiving psychopharmacological treatments should be monitored closely for evidence of efficacy, side effects, toxicity, and interactions with other medications. They should also be considered for evidence-based psychotherapeutic interventions and caregiver supports.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Recommendations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The likelihood of possible benefits with all medications used to treat BD in older adults needs to be balanced against potential risks. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Polypharmacy in older adults should be avoided. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lithium can be used in older adults to treat acute mania, as maintenance, and also to treat bipolar depression. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Overall, valproate appears to be better tolerated than lithium in older adult patients with BD. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Carbamazepine is an alternative treatment to lithium for older patients with severe cardiovascular or renal disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally, benzodiazepines should be used with caution. However, they may be needed to treat extreme agitation. Care should be taken in the presence of comorbid medical conditions or possible drug-drug interactions. Older adults may be more sensitive than younger adults to central effects of benzodiazepines leading to ataxia, confusion, disinhibition, and delirium. If needed, a shorter-acting benzodiazepine which is metabolized by conjugation could be used, e.g., lorazepam. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The role of antidepressants in the management of BD is complex and sometimes controversial. Older adults are more likely than younger adults to develop initial manic episodes during antidepressant therapy. The provider should use tricyclics with caution in the older populations as these have been shown to cause an increased risk of treatment-emergent affective switches in this age group. It has been reported that the first line treatments for bipolar depression are mood stabilizers, and that adjunctive antidepressants should be used with caution. However, older adults with BD treated with a mood stabilizer and an antidepressant may be less likely to attempt suicide. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The treatment of secondary mania in older adults is relatively similar to the treatment of primary mania and typically does not usually require prophylaxis unlike primary mania. However, there may be increased sensitivity to side effects of medications, so dosages should be modified. Mania associated with structural central nervous system disease may respond better to carbamazepine or valproate. Newer anticonvulsant agents, such as topiramate and lamotrigine, have not been specifically studied yet in this patient population. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The preferred treatment for older adults with acute mania is an atypical antipsychotic (e.g., risperidone, quetiapine, olanzapine, and aripiprazole) combined with a mood stabilizer. Comorbid medical conditions such as diabetes, constipation, hypotension, weight may influence medication choice. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The provider needs to consider that mood stabilizers may impact cognitive functioning in older adults. Adverse effects were reported to be least likely in those taking lamotrigine or oxcarbazepine, intermediate with lithium, and greatest with valproate, carbamazepine, and topiramate. In a study of older adults with BD, lithium was no more likely to impair cognition than other therapies, but this study was limited by low statistical power. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is growing concern regarding metabolic issues related to second-generation antipsychotics. The risk is greatest with clozapine and olanzapine, followed by quetiapine and risperidone, and then followed by aripiprazole and ziprasidone. If an older individual is to be maintained on a second-generation antipsychotic, baseline measures of weight, waist circumference, fasting blood glucose, and glycosylated hemoglobin (HbA1c) should be obtained. Weight or waist circumference can be monitored every two months and fasting blood glucose checked every six months or sooner if there is significant weight gain. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All pharmacological interventions for older adults with BD should be combined with cognitive, behavioral, family, interpersonal and social rhythm therapies in conjunction with psychoeducation and chronic disease management. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Quality of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one properly done randomized controlled trial (RCT)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-1&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-designed controlled trial without randomization&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-2&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-designed cohort or case-control analytic study, preferably from more than one source&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;II-3&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Multiple time series evidence with/without intervention, dramatic results of uncontrolled experiment&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Opinion of respected authorities, descriptive studies, case reports, and expert committees&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Overall Quality&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Overall Quality&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-grade evidence (I or II-1) directly linked to health outcome&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Fair&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High-grade evidence (I or II-1) linked to intermediate outcome; &lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Moderate-grade evidence (II-2 or II-3) directly linked to health outcome&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Poor&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level III evidence or no linkage of evidence to health outcome&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Net Effect of the Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Net Effect of the Intervention&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Substantial&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;More than a small relative impact on a frequent condition with a substantial burden of suffering;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            A large impact on an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A small relative impact on a frequent condition with a substantial burden of suffering;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            A moderate impact on an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Small&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A negligible relative impact on a frequent condition with a substantial burden of suffering;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            A small impact on an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Zero or Negative&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Negative impact on patients;&lt;br /&gt;&#xD;&#xA;            &lt;strong&gt;or&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            No relative impact on either a frequent condition with a substantial burden of suffering, or an infrequent condition with a significant impact on the individual patient level&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Final Grade of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Final Grade of Recommendation&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;4&quot;&gt;The Net Benefit of the Intervention&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Substantial&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Small&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Zero or negative&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Good&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Fair&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Poor&lt;/th&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations Rating System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Strength of Recommendations Rating System&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A strong recommendation that the clinicians provide the intervention to eligible patients.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;Good evidence was found that the intervention improves important health outcomes and concludes that benefits substantially outweigh harm&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A recommendation that clinicians provide (the service) to eligible patients.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;At least fair evidence was found that the intervention improves health outcomes and concludes that benefits outweigh harm&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No recommendation for or against the routine provision of the intervention is made.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;At least fair evidence was found that the intervention can improve health outcomes, but concludes that the balance of benefits and harms is too close to justify a general recommendation&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendation is made against routinely providing the intervention to asymptomatic patients.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;At least fair evidence was found that the intervention is ineffective or that harms outweigh benefits&lt;/em&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention. &lt;br /&gt;&#xD;&#xA;            &lt;em&gt;Evidence that the intervention is effective is lacking, or poor quality, or conflicting, and the balance of benefits and harms cannot be determined.&lt;/em&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms are provided in the &lt;a href=&quot;http://www.healthquality.va.gov/bipolar/bd_305_full.pdf&quot; title=&quot;Department of VA Web site&quot; target=&quot;_blank&quot;&gt;original guideline document&lt;/a&gt; for:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Current Mania, Hypomania or Mixed Episode &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Current Bipolar Depressive Episode &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maintenance &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline is based on an exhaustive review of the literature. Where existing literature was ambiguous or conflicting, or where scientific data were lacking on an issue, recommendations were based on the clinical experience of the Working Group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The type of supporting evidence is identified for selected recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriate management of bipolar disorder in adults &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Efficient and effective assessment of patient's complaints &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optimization of the use of therapy to control symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Minimization of preventable complications and morbidity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Satisfaction and positive attitudes regarding management of psychosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Promotion of patient recovery to the fullest extent &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Adverse Effects of Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Lithium&lt;/em&gt;: See Table E - 1, &quot;Adverse Events&amp;mdash;Lithium,&quot; in the original guideline document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Antiepileptics&lt;/em&gt;: See Table E - 4, &quot;Adverse Events&amp;mdash;Antiepileptic Medications,&quot; in the original guideline document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The provider needs to consider that mood stabilizers may impact cognitive functioning in older adults. Adverse effects were reported to be least likely in those taking lamotrigine or oxcarbazepine, intermediate with lithium, and greatest with valproate, carbamazepine, and topiramate. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Antipsychotics&lt;/em&gt;: neuroleptic malignant syndrome (NMS)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;See Table E - 6, &quot;Adverse Events&amp;mdash;Antipsychotics,&quot; in the original guideline document. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;There is growing concern regarding metabolic issues related to second-generation antipsychotics in older adults. The risk is greatest with clozapine and olanzapine, followed by quetiapine and risperidone, and then followed by aripiprazole and ziprasidone. If an older individual is to be maintained on a second-generation antipsychotic, baseline measures of weight, waist circumference, fasting blood glucose, and glycosylated hemoglobin (HbA1c) should be obtained. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Antidepressants&lt;/em&gt;:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;See Table E - 9, &quot;Adverse Events&amp;mdash;Antidepressants,&quot; in the original guideline document. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Older adults are more likely than younger adults to develop initial manic episodes during antidepressant therapy. The provider should use tricyclics with caution in the older populations as these have been shown to cause an increased risk of treatment-emergent affective switches in this age group. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Refer to Module E in the original guideline document for detailed information on adverse effects of medications used for treatment of bipolar disorder. See also Appendix D in the original guideline for precautions in special populations (renal, hepatic, and cardiac impairment; pregnancy; and breastfeeding).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Electroconvulsive Therapy (ECT)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ECT may cause adverse cognitive effects. Pertinent preexisting medical conditions that put patients at higher risk of complications include hypertension, coronary artery disease, congestive heart failure, aortic stenosis, implanted cardiac devices, atrial fibrillation, obstructive lung disease, and asthma.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Lithium&lt;/em&gt; is to be avoided in the first trimester of pregnancy due to the risk of fetal Ebstein's anomaly with a risk that is 10 to 20 times greater than the general population. Lithium is contraindicated during breastfeeding due to concerns of infant lithium toxicity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Appendix D in the original guideline document for more information.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Department of Veterans Affairs (VA) and The Department of Defense (DoD) guidelines are based on the best information available at the time of publication. They are designed to provide information and assist in decision-making. They are not intended to define a standard of care and should not be construed as one. Also, they should not be interpreted as prescribing an exclusive course of management. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Variations in practice will inevitably and appropriately occur when providers take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in any particular clinical situation. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline and algorithms are designed to be adapted by individual facilities in considering needs and resources. The algorithms serve as a guide that providers can use to determine best interventions and timing of care for their patients to optimize quality of care and clinical outcomes. This should not prevent providers from using their own clinical expertise in the care of an individual patient. Guideline recommendations are intended to support clinical decision-making and should never replace sound clinical judgment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although this guideline represents the state of the art practice on the date of its publication, medical practice is evolving and this evolution requires continuous updating of published information. New technology and more research will improve patient care in the future. The clinical practice guideline can assist in identifying priority areas for research and optimal allocation of resources. Future studies examining the results of clinical practice guidelines such as these may lead to the development of new practice-based evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Management of Bipolar Disorder Working Group. VA/DoD clinical practice guideline for management of bipolar disorder in adults. Washington (DC): Department of Veterans Affairs, Department of Defense; 2010 May. 176 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;In the development of this guideline, the Working Group relied heavily on the following evidence-based guidelines:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Practice guideline for the treatment of patients with bipolar disorder, second edition. American Psychiatric Association (APA) Steering Committee on Practice Guidelines, 2002; APA Practice Guidelines. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Institute for Health and Clinical Excellence (NHS). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London (UK), NICE Clinical Guideline 38. National Collaborating Centre for Mental Health; July 2006. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 2009; 11: 225-55. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 May" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Department of Defense - Federal Government Agency [U.S.]" /><FieldValue Value="Department of Veterans Affairs - Federal Government Agency [U.S.]" /><FieldValue Value="Veterans Health Administration - Federal Government Agency [U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;United States Government&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Management of Bipolar Disorder Working Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Working Group Members (VA)&lt;/em&gt;: Eileen P. Ahearn, MD, PhD; Thomas J. Craig, MD, MPH; Jennifer Hoblyn, MD, MPH; Amy M. Kilbourne*, PhD, MPH; Todd P. Semla*, PharmD; Alan C. Swann*, MD; Trisha Suppes*, MD, PhD (&lt;em&gt;Co-Chair&lt;/em&gt;); Michael Thase*, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Working Group Members (DoD)&lt;/em&gt;: Aaron Bilow, PharmD; Gary Southwell*, PhD LTC, USA; Randon S. Welton*, MD, LtCol, USAF (&lt;em&gt;Co-Chair&lt;/em&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Office of Quality and Performance, VHA&lt;/em&gt;: Carla Cassidy, RN, MSN, NP&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Quality Management Division, U.S. Army Medical Command&lt;/em&gt;: Ernest Degenhardt, RN, MSN, ANP-FNP; Joanne Ksionzky, BSN, RN, CNOR, RNFA; Mary Ramos, PhD, RN&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Facilitator&lt;/em&gt;: Oded Susskind*, MPH&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Research Team &amp;ndash; ECRI Institute&lt;/em&gt;: Vivian H. Coates, MPH; Eileen G. Erinoff; Karen Schoelles, MD; David Snyder, PhD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Healthcare Quality Informatics, Inc.&lt;/em&gt;: Martha D'Erasmo, MPH; Rosalie Fishman, RN, MSN, CPHQ; Joanne Marko, MS, SLP&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;* Members of the CORE Editorial Panel&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.healthquality.va.gov/Management_of_Bi.asp&quot; title=&quot;Department of VA Web site&quot; target=&quot;_blank&quot;&gt;Department of Veterans Affairs Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Department of Veterans Affairs, Veterans Health Administration, Office of Quality and Performance (10Q) 810 Vermont Ave. NW, Washington, DC 20420.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;VA/DoD clinical practice guideline for the management of bipolar disorder in adults. Guideline summary. Washington (DC): Department of Veterans Affairs (U.S.); 2010 May. 78 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.healthquality.va.gov/bipolar/bd_306_sum.pdf&quot; title=&quot;Department of VA Web site&quot; target=&quot;_blank&quot;&gt;Department of Veterans Affairs Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Department of Veterans Affairs, Veterans Health Administration, Office of Quality and Performance (10Q) 810 Vermont Ave. NW, Washington, DC 20420.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on October 12, 2010. This summary was updated by ECRI Institute on May 20, 2011 following the U.S. Food and Drug Administration advisory on antipsychotic drugs. This summary was updated by ECRI Institute on July 10, 2013 following the U.S. Food and Drug Administration advisory on Valproate. This summary was updated by ECRI Institute on December 18, 2014 following the U.S. Food and Drug Administration advisory on Ziprasidone. This summary was updated by ECRI Institute on October, 5 2015 following the U.S. Food and Drug Administration advisory on Clozapine.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No copyright restrictions apply.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
